Leadership

  • Print

Executive Leadership

 

Julie Kliegl

  

Julie Kliegl, PhD, President

Julie Kliegl is the Company’s President. Prior to joining Viracor Eurofins in May 2015, Ms. Kliegl was Vice President, Employee & Customer Services at Boston Heart Diagnostics, a leader in personalized cardiovascular diagnostics and lifestyle services. Ms. Kliegl has over 25 years of diverse business experience with organizations including Quest Diagnostics, where she held positions of increasing responsibility over a 15-year career with the company. One of her key accomplishments at Quest Diagnostics was working on merger and integration planning between the company and SmithKline Clinical Laboratories. Her background in clinical diagnostics involves senior-level work in a wide range of functions including sales, operations, human resources, business development and communications. Ms. Kliegl is also a Leadership Fellow and tenured professor of business administration. She has presented at numerous academic conferences including the Academy of Management, the Midwest Academy of Management and the Collaboration for Learning. She obtained a Bachelor of Arts degree in economics from Coe College, an MBA from New York University, Stern School of Business and a doctorate in organizations and management from Capella University. Ms. Kliegl is also active on the boards of several corporate and non-profit organizations.

 

Michelle Altrich

  

Michelle Altrich, PhD, HCLD, Chief Scientific Officer and Clinical Laboratory Director

Dr. Altrich is the Chief Scientific Officer and Clinical Laboratory Director at Viracor Eurofins. In her previous role at IBT, Dr. Altrich was responsible for new test development in the area of cellular function testing for allergy and autoimmune diseases as well as serving as the Assistant Lab Director for IBT's menu of immunodiagnostic tests. Dr. Altrich joined IBT in 2006 as a Senior Scientist. Prior to joining IBT, Dr. Altrich held an appointment at the University of Virginia in Charlottesville where she specialized in molecular and cellular immunology. Dr. Altrich received her PhD in pathology and microbiology from the University of Nebraska Medical Center where her research focused on tumor immunology.

 

Steve Kleiboeker

  

Steven Kleiboeker, PhD, HCLD/TS/CC(ABB), Vice President, Research & Development

Steven Kleiboeker, PhD, Vice President of Research and Development, is responsible for the scientific direction and oversight of the Company's research and development programs as well as the BioPharma Clinical Trials research services. The Viracor Eurofins R&D team performs method discovery, development and validation for assays performed in Viracor Eurofins' clinical and BioPharma Clinical Trials testing laboratories in the fields of molecular infectious diseases, immunology and allergy. Dr. Kleiboeker is board certified as a high-complexity laboratory director, technical supervisor and clinical consultant by the American Board of Bioanalysis. Over his career, he has published more than 60 scientific manuscripts and serves on editorial boards and as a reviewer for several virological and microbiological journals. Prior to joining Viracor Eurofins in 2005, Dr. Kleiboeker was a faculty member at the University of Missouri where his duties included research, graduate teaching, and supervision of three university-based diagnostic service laboratories (virology, serology and molecular diagnostics). His research has focused on viral pathogenesis, phylogenetics and diagnostics and has included projects investigating a broad range of human and animal pathogens. Dr. Kleiboeker has served as both principal investigator and co-investigator on numerous government-funded research grants (NIH, USDA). Dr. Kleiboeker received his PhD and DVM from the University of Missouri.

 

Vicki Schluter

  

Vicki Schluter, Vice President and Chief Information Officer

Vicki Schluter serves as Vice President and Chief Information Officer. She is responsible for providing innovative technology solutions that enable the company's strategy. Prior to Viracor Eurofins, Ms. Schluter was Vice President of Technology for YRC Worldwide, a global transportation service provider. At YRC, she was responsible for the development and support of all applications. This encompassed sales and order placement, freight movement, customer service, human resources and finance, electronic data interchange, and mobile and web applications. Ms. Schluter also led the technology effort to successfully combine Yellow and Roadway as YRC. Prior to leading technology at YRC Worldwide, she held various technical and leadership positions in the Industrial Engineering department of Yellow Transportation. Ms. Schluter holds a BS degree in Industrial Engineering and a Master of Science degree in Industrial Engineering from Iowa State University.

 

Michael Seymour

  

Michael Seymour, Manager, Regulatory Affairs/Quality Assurance

Michael Seymour serves as Manager of Regulatory Affairs and Quality Assurance where he oversees the company’s Quality Management System including all aspects of clinical laboratory and medical device manufacturing licensure and accreditation, inspection readiness, external audits and the internal auditing program. Since joining Viracor Eurofins in 2008, Mr. Seymour led the redesign of the company’s validation process resulting in receiving a limited exemption from submission of individual validation packages for Virology assays with the New York State Department of Health. Mr. Seymour is a Certified Quality Auditor through American Society for Quality and holds a BS in chemistry from Creighton University.

 

Matt Urbanek

  

Matt Urbanek, Executive Vice President and Chief Financial Officer; Chief Compliance Officer

Matt Urbanek serves as Executive Vice President and Chief Financial Officer. He is responsible for all financial, legal, tax and treasury functions within Viracor Eurofins, and also serves as the Company’s Chief Compliance Officer.  During his tenure, Mr. Urbanek has also overseen Viracor Eurofins' logistics, client services and information technology functions.  He was also responsible for all finance and logistics functions at ViraCor before the company merged with IBT in 2009. Prior to joining ViraCor, Mr. Urbanek was a Vice President at George K. Baum Advisors, LLC, an investment-banking firm that specializes in mergers and acquisitions, raising private capital and financial advisory services for middle-market companies. In this role he initiated and executed mergers, acquisitions, divestitures and financings, as well as business valuations, fairness opinions and board advisory services for clients in the business services sector. Mr. Urbanek earned a BA in business administration and finance and a BS in economics from Kansas State University.  He is a member of the Finance Advisory Board for Kansas State University’s Department of Finance.

Scientific Leadership

 

Linda Flebbe-Rehwaldt

  

Linda Flebbe-Rehwaldt, PhD, Senior Scientist

Linda Flebbe-Rehwaldt is a Senior Scientist focused on new test development for allergy and clinical immunology. Dr. Flebbe-Rehwaldt joined Viracor Eurofins laboratories in 2010 and is currently working on developing cellular immunology and immunochemistry assays. Prior to joining Viracor Eurofins she held an appointment at the University of California, San Francisco working on gene delivery mechanisms for gene therapy. Her postdoctoral training was at UCSF studying regulatory elements of the human beta hemoglobin complex. She received her PhD from the University of Kansas Medical Center.

 

Amanda Hays

  

Amanda Hays, PhD, Senior Scientist

Amanda Hays is a Senior Research Scientist focused on the development of novel and innovative clinical assays. Dr. Hays joined Viracor Eurofins in 2014 and is currently working on development, implementation and optimization of drug-induced immunogenicity assays on various platforms. Prior to joining Viracor Eurofins, she worked in the field of drug metabolism and developed extensive high-throughput assays for drug-drug and drug-therapeutic protein interactions. Dr. Hays received her PhD in Pharmacology from the University of Kansas Medical Center where she studied the characterization of drug transport proteins in cancer cells to improve diagnostics and drug delivery.

 

Marilyn Smith

  

Marilyn Smith, PhD, Senior Scientist

Marilyn Smith is a Senior Scientist focused on new molecular assay development. Dr. Smith has over 30 years experience in virology, microbiology, and molecular biology and has successfully developed many commercial assays. Prior to joining IBT in 2007, Dr. Smith was Research Associate Professor of Microbiology at the University of Kansas Medical Center, where she worked on viral evolution, pathogenesis, and vaccine studies in a primate model of HIV-1 infection. Earlier in her career, she led a subproject on the development of HIV-1 resistance to antivirals for the UNC AIDS Clinical Trials Unit grant. She earned her PhD at the University of Minnesota and was a postdoctoral fellow at the Clinical Research Institute of Montreal and at the Lineberger Comprehensive Cancer Research Center, UNC-Chapel Hill.

 

Mark Wissel

  

Mark Wissel, PhD, Senior Scientist

Mark Wissel is the company's Assistant Director for Clinical Mycology. Dr. Wissel has been a Senior Scientist directing the development of fungal diagnostic assays at Viracor Eurofins since 2006. Prior to joining Viracor Eurofins, he was a Post-Doctoral Fellow in the Department of Microbiology, Molecular Genetics and Immunology  at the University of Kansas Medical Center where he conducted research into the molecular mechanisms of bacterial cell division.  He received his PhD in Microbiology from the University of Iowa College of Medicine.

 

Mark Mendels

  

Marc Mendels, Senior Director, Clinical Products

Marc Mendels is the Medical Science Liaison at Viracor Eurofins, in the Scientific Affairs department. He joined Viracor Eurofins in February 2013, following 25 years of experience in solid organ transplant immunosuppression at companies that included Ortho-Biotech (Johnson & Johnson), Fujisawa (Astellas), Wyeth (Pfizer), and Cylex. In that prior experience, he was an integral member of teams that managed the first FDA-approved monoclonal antibody for therapeutic use (OKT3®), and subsequently launched and managed organ transplant immunosuppressant drugs that included Prograf® (tacrolimus) and Rapamune® (sirolimus). He was then recruited to Cylex as the company’s first medical science liaison, managing medical affairs field responsibilities in regards to the immune cell function assay ImmuKnow®. His 17 years as a medical science liaison include extensive experience in clinical research, scientific presentations and medical affairs management. He has post-graduate training in advanced immunology, and is regarded by the transplant medical community as the expert in the utility of ImmuKnow® in populations undergoing immunosuppressive therapy for organ transplantation.